3 UK Stocks Estimated To Be 21.1% To 46.6% Below Intrinsic Value
The United Kingdom's stock market has recently faced challenges, with the FTSE 100 closing lower due to weak trade data from China and declining commodity prices affecting major companies. In this environment of uncertainty, investors may be on the lookout for stocks that are undervalued relative to their intrinsic value, as these can present potential opportunities despite broader market fluctuations.
Name
Current Price
Fair Value (Est)
Discount (Est)
Begbies Traynor Group (AIM:BEG)
£0.916
£1.68
45.6%
Savills (LSE:SVS)
£9.27
£16.53
43.9%
Gooch & Housego (AIM:GHH)
£3.77
£7.13
47.1%
Aptitude Software Group (LSE:APTD)
£2.79
£5.13
45.7%
GlobalData (AIM:DATA)
£1.775
£3.32
46.6%
On the Beach Group (LSE:OTB)
£2.65
£4.78
44.5%
Entain (LSE:ENT)
£6.376
£12.03
47%
ECO Animal Health Group (AIM:EAH)
£0.695
£1.28
45.6%
Kromek Group (AIM:KMK)
£0.051
£0.10
49.7%
Ibstock (LSE:IBST)
£1.80
£3.24
44.5%
Click here to see the full list of 52 stocks from our Undervalued UK Stocks Based On Cash Flows screener.
Here's a peek at a few of the choices from the screener.
Overview: GlobalData Plc, along with its subsidiaries, offers business information through proprietary data, analytics, and insights across Europe, North America, and the Asia Pacific with a market cap of £1.35 billion.
Operations: The company's revenue is derived from its Data, Analytics and Insights segments, with £109.40 million from Healthcare and £176.10 million from Non-Healthcare sectors.
Estimated Discount To Fair Value: 46.6%
GlobalData is trading at £1.78, significantly below its estimated fair value of £3.32, indicating it may be undervalued based on cash flows. Despite a volatile share price and a reduced dividend, the company is forecast to grow earnings by 21% annually, outpacing the UK market's growth rate. Recent M&A interest from ICG and KKR highlights potential strategic value, while an active share buyback program aims to enhance shareholder returns amidst plans to move to the Main Market.
Our earnings growth report unveils the potential for significant increases in GlobalData's future results.
Delve into the full analysis health report here for a deeper understanding of GlobalData.
Overview: AstraZeneca PLC is a biopharmaceutical company engaged in the discovery, development, manufacture, and commercialization of prescription medicines, with a market cap of approximately £166.35 billion.
Operations: The company's revenue primarily stems from its biopharmaceuticals segment, which generated $54.98 billion.
Estimated Discount To Fair Value: 42.9%
AstraZeneca is currently trading at £107.28, well below its estimated fair value of £187.75, highlighting potential undervaluation based on cash flows. Despite a recent decision to discontinue the CAPItello-280 trial, AstraZeneca's earnings are projected to grow 14.5% annually, surpassing UK market averages. The company reported strong Q1 results with revenue of US$13.59 billion and net income of US$2.92 billion, reflecting robust financial health despite high debt levels and large one-off items impacting results.
Our growth report here indicates AstraZeneca may be poised for an improving outlook.
Navigate through the intricacies of AstraZeneca with our comprehensive financial health report here.
Overview: Bridgepoint Group plc is a private equity and private credit firm focusing on middle market, lower mid-market, small mid cap, small cap, growth capital, buyouts investments, syndicate debt, infrastructure, direct lending and credit opportunities in private credit investments with a market cap of £2.21 billion.
Operations: The company's revenue is derived from four main segments: Credit (£75.70 million), Infrastructure (£72.50 million), and Private Equity (£275.60 million).
Estimated Discount To Fair Value: 21.1%
Bridgepoint Group is trading at £2.67, over 20% below its estimated fair value of £3.39, indicating potential undervaluation based on cash flows. Despite a volatile share price and lower profit margins compared to the previous year, earnings are forecast to grow significantly at 32.63% annually, outpacing the UK market average. Recent revenue growth and a proposed dividend increase reflect positive momentum, although large one-off items have impacted financial results.
Insights from our recent growth report point to a promising forecast for Bridgepoint Group's business outlook.
Click here and access our complete balance sheet health report to understand the dynamics of Bridgepoint Group.
Gain an insight into the universe of 52 Undervalued UK Stocks Based On Cash Flows by clicking here.
Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AIM:DATA LSE:AZN and LSE:BPT.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Canada announces new aid to Ukraine worth approximately US$25.5 million
Canada is providing Ukraine with military aid worth over 35 million Canadian dollars (approximately US$25.5 million). Source: Canada's Defence Ministry press service, as reported by European Pravda Details: Canadian Defence Minister David J. McGuinty took part in the 28th meeting of the Ukraine Defence Contact Group (also known as the Ramstein Format). At the meeting, McGuinty announced that Canada is providing Ukraine with military aid worth 35 million Canadian dollars. He said that 30 million Canadian dollars (US$21.9 million) will be spent on Coyote and Bison armoured personnel carriers, as well as new equipment and ammunition from Canadian companies. This is in addition to the previous transfer of 64 Coyote armoured vehicles, which arrived in Ukraine in December 2024. Another 5 million Canadian dollars (US$3.6 million) will go towards electronic warfare kits from the Canadian defence industry. Background: At the 28th Ramstein meeting, held at NATO headquarters, Ukraine and its partner countries agreed to create a defence production mechanism. The US secretary of defence ignored the Ramstein meeting for the first time. Support Ukrainska Pravda on Patreon!
Yahoo
an hour ago
- Yahoo
Beef prices surge as barbecue season approaches
Canadians looking to grill some burgers and steaks as the summer barbecue season heats up may find themselves paying much more for beef, prompting one food expert to call for an investigation. Prices for striploin steak are 34.2 per cent higher since January, while top sirloin is up 33.7 per cent, according to Statistics Canada. Pork ribs and chicken breasts are each up 5.9 per cent during the same period. 'For many Canadian families, a summer steak on the grill is starting to feel more like a splurge than a staple,' Sylvain Charlebois, director of the Agri-Food Analytics Lab at Dalhousie University, said in a recent report. 'Consumers will continue to enjoy beef, but with moderation and on occasions that justify the cost.' He pointed to several factors behind the jump in beef prices, including transportation costs, the carbon tax, the number of licensed beef processors and labour costs. Canadian inventory is also an issue since it has fallen to 3.38 million head, the lowest level since 1989. 'Many cattle producers are exiting the industry while prices are favourable, opting to reinvest in less volatile sectors or shift entirely to crop production,' Charlebois said. 'In short, the Canadian beef industry is retreating and becoming increasingly risk-averse.' Canadians are already taking notice of the price hikes in the past few years. Per capita beef consumption fell 7.1 per cent in 2023 and another 2.1 per cent in 2024, according to IBISWorld data. 'This is no longer just a matter of shifting dietary preferences; it's a structural shift in consumer behaviour,' Charlebois said. 'Beef is increasingly seen as a luxury item, with ground beef becoming the primary choice for budget-conscious households still committed to red meat.' He also wonders if producers in Canada are taking advantage of the situation. In the United States, former president Joe Biden tried to crack down on anticompetitive practices in the food industry, specifically price fixing in the meat sector. In February, Brazilian meatpacking company JBS SA agreed to pay US$83.5 to settle claims that it worked with other companies to artificially inflate prices. Under the settlement, JBS must also work with U.S. investigators looking into similar claims at Tyson Foods Inc., Cargill Inc. and National Beef Packing Co. LLC. JBS has called the claims against it 'frivolous and without merit,' but is settling because it is in the company's best interest. 'The Canadian Competition Bureau, by contrast, has remained largely silent on similar concerns,' Charlebois said. 'Perhaps it's time for that to change.' Prices on thousands of grocery items to rise despite tariff break, says Loblaw Canada has lost its global agricultural trading edge, RBC report says The Competition Bureau said investigations are confidential, so it can not reveal information on current investigations. 'The bureau must conduct a thorough and complete examination of the facts regarding any issue before reaching any conclusion as to whether the Competition Act has been contravened,' a spokesperson for the agency said in a statement. 'If we find evidence of activities that could raise concerns under the law, we will take action.' • Email: bcousins@ Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to use the Zacks Style Scores, which are indicators that rate stocks based on three widely-followed investing types: value, growth, and momentum. Different than value or momentum investors, growth-oriented investors are concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, they'll want to focus on the Growth Style Score, which analyzes characteristics like projected and historical earnings, sales, and cash flow to find stocks that will see sustainable growth over time. AstraZeneca plc, headquartered in London, UK, is one of the largest biopharmaceutical companies in the world. AstraZeneca was formed on Apr 6, 1999, through the merger of Sweden's Astra AB and UK's Zeneca Group plc. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include CVRM (cardiovascular, renal and metabolism), Respiratory & Immunology (R&I), Oncology, Rare Diseases, Vaccines and Other. AZN sits at a Zacks Rank #3 (Hold), holds a Growth Style Score of B, and has a VGM Score of A. Earnings and sales are forecasted to increase 9.3% and 6.7% year-over-year, respectively. Two analysts revised their earnings estimate higher in the last 60 days for fiscal 2025, while the Zacks Consensus Estimate has increased $0 to $4.49 per share. AZN also boasts an average earnings surprise of 4.2%. On a historic basis, Astrazeneca has generated cash flow growth of 18.6%, and is expected to report cash flow expansion of 16.7% this year. Investors should take the time to consider AZN for their portfolios due to its solid Zacks Rank rating, notable growth metrics, and impressive Growth and VGM Style Scores. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
